52: A Single Dose of Gemtuzumab-Ozogamicin (GO) in Consolidation Prior to Autologous Transplant for Younger Patients with Newly Diagnosed Acute Myeloid (AML) is Safe But Has No Effect on Disease Free Survival: Interim Results of Eastern Cooperative Oncology Group Study (E1900)
Year: 2008
Type: article
Abstract: Gemtuzumab-Ozogamicin (GO), a CD33 directed monoclonal antibody linked to calicheamicin, was developed to provide targeted therapy for patients with AML. The addition of GO to standard induction therapy has had promising results, particularly in its ability to induce complete remission (CR). Its role in consolidation therapy in AML is not defined and therefore, the main objective of E1900 was to compare the disease-free survival (DFS) of adult patients with newly diagnosed AML, age 60 or less, between two consolidation regimens: Group A received high-dose cytarabine, 3 gm/m2 every 12 hours days 1, 3 and 5 for a total of 6 doses, for two cycles, collected autologous peripheral blood stem cells (PBSC), then proceeded to autologous transplant with high-dose intravenous busulfan and cyclophosphamide with PBSC support.
Authors: H.F. Fernandez, Z. Sun, J.M. Bennett, E.M. Paietta, M.R. Litzow, J.M. Rowe, M.S. Tallman, H.M. Lazarus
Institutions: Moffitt Cancer Center, Eastern Cooperative Oncology Group, University of Rochester, Lady of Mercy Medical Center, Mayo Clinic, Rambam Health Care Campus, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Case Comprehensive Cancer Center, Case Western Reserve University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2017220251